TransEnterix to Feature Senhance™ Surgical Robot at American College of Surgeons Clinical Congress

TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance™ Surgical Robot (“the Senhance” or “the Senhance system”) at the Clinical Congress 2016 of the American College of Surgeons (ACS). The congress will be held on October 16-20, 2016 in Washington, DC.
“ACS is the largest gathering of global surgeons, and we are pleased to
bring the Senhance System to exhibit at this major meeting for the first
time,” said Mohan Nathan, Vice President of Global Marketing at
TransEnterix. “General surgical interest in the use of robotics is
rapidly expanding, and the next wave of adoption will be driven by
providing surgeons with new capabilities. Senhance is the first system
that brings haptic force feedback, eye-sensing camera control, and
responsible economics through reusable instrumentation to robotics.”
The Senhance will be available for surgeon evaluations at the congress.
Surgeons may schedule system evaluations by signing up at the
TransEnterix booth. Non-surgeons may see demonstrations throughout the
conference, and may also attend a group demonstration at the booth at
10am on Tuesday, October 18, 2016.
The Senhance carries the CE Mark for use in general surgery, gynecology,
urology and thoracic surgery but is not available for sale in the US.
TransEnterix is preparing a submission for U.S. FDA Clearance for the
Senhance.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of
robotics to improve minimally invasive surgery by addressing the
clinical and economic challenges associated with current laparoscopic
and robotic options. The company is focused on the commercialization of
the Senhance Surgical Robotic System, a multi-port robotic system that
brings the advantages of robotic surgery to patients while enabling
surgeons with innovative technology such as haptic feedback and eye
sensing camera control. The company is also developing the SurgiBot™
System, a single-port, robotically enhanced laparoscopic surgical
platform. The Senhance Surgical Robotic System has been granted a CE
Mark but is not currently available for sale in the United States. For
more information, visit the TransEnterix website at www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to The Senhance™
Surgical Robotic System and the SurgiBot™ System and our current
regulatory and commercialization plans for these products. These
statements and other statements regarding our future plans and goals
constitute “forward looking statements” within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe harbor
from liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which may
cause results to differ materially from expectations. For a discussion
of the risks and uncertainties associated with TransEnterix’s business,
please review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K filed on March 3, 2016
and our other filings we make with the SEC. You are cautioned not to
place undue reliance on these forward looking statements, which are
based on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.